EA199800861A1 - Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка - Google Patents

Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка

Info

Publication number
EA199800861A1
EA199800861A1 EA199800861A EA199800861A EA199800861A1 EA 199800861 A1 EA199800861 A1 EA 199800861A1 EA 199800861 A EA199800861 A EA 199800861A EA 199800861 A EA199800861 A EA 199800861A EA 199800861 A1 EA199800861 A1 EA 199800861A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cisapride
solid
cyzprid
preparation
product
Prior art date
Application number
EA199800861A
Other languages
English (en)
Other versions
EA000804B1 (ru
Inventor
Пауль Мари Виктор Гилис
Гвидо Францискус Сманс
Гвидо Йозеф Мария Гейс
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Publication of EA199800861A1 publication Critical patent/EA199800861A1/ru
Publication of EA000804B1 publication Critical patent/EA000804B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к твердым лекарственным формам некоторых солей цизаприда, конкретнее - цизаприд-(L)-тартрата, цизаприд-(D)-тартрата, цизаприд сульфата, цизаприд цитрата, которые не вступают во взаимодействие с пищей и допускают одновременное назначение лекарственных средств, повышающих pH в желудке. Это изобретение в особенности относится к твердым лекарственным формам, способным быстро растворяться. Настоящее изобретение также относится к таблеткам, которые можно изготавливать путем непосредственного прессования.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800861A 1996-04-23 1997-03-20 Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка EA000804B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23
PCT/EP1997/001462 WO1997039744A1 (en) 1996-04-23 1997-03-20 Immediate release ph-independent solid dosage form of cisapride

Publications (2)

Publication Number Publication Date
EA199800861A1 true EA199800861A1 (ru) 1999-02-25
EA000804B1 EA000804B1 (ru) 2000-04-24

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800861A EA000804B1 (ru) 1996-04-23 1997-03-20 Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка

Country Status (23)

Country Link
US (1) US6030988A (ru)
JP (1) JPH10510559A (ru)
KR (1) KR100204115B1 (ru)
CN (1) CN1216467A (ru)
AR (1) AR006790A1 (ru)
AT (1) ATE220543T1 (ru)
AU (1) AU720582B2 (ru)
BG (1) BG102812A (ru)
BR (1) BR9708585A (ru)
CA (1) CA2201264C (ru)
CZ (1) CZ332598A3 (ru)
DE (1) DE69713948D1 (ru)
EA (1) EA000804B1 (ru)
EE (1) EE03552B1 (ru)
ID (1) ID16666A (ru)
IL (1) IL125979A0 (ru)
NO (1) NO984016L (ru)
NZ (1) NZ331705A (ru)
PL (1) PL328917A1 (ru)
SK (1) SK144698A3 (ru)
TR (1) TR199802139T2 (ru)
WO (1) WO1997039744A1 (ru)
ZA (1) ZA973449B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2387746C (en) 1999-10-20 2010-06-29 Koji Ukai Methods for stabilizing benzimidazole-based compounds
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
DE10164510A1 (de) 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA2139636A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
ATE182073T1 (de) * 1994-03-01 1999-07-15 Gerhard Gergely Ein brausesystem und einen arzneiwirkstoff enthaltendes granuläres produkt bzw. tablette sowie verfahren zu deren herstellung
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
KR100204115B1 (ko) 1999-06-15
DE69713948D1 (de) 2002-08-22
CZ332598A3 (cs) 1999-01-13
CN1216467A (zh) 1999-05-12
EE03552B1 (et) 2001-12-17
NO984016L (no) 1998-12-23
CA2201264C (en) 1999-08-10
TR199802139T2 (xx) 1999-03-22
ATE220543T1 (de) 2002-08-15
BG102812A (en) 1999-05-31
JPH10510559A (ja) 1998-10-13
AR006790A1 (es) 1999-09-29
ZA973449B (en) 1998-10-22
BR9708585A (pt) 1999-08-03
CA2201264A1 (en) 1997-10-23
NO984016D0 (no) 1998-09-01
US6030988A (en) 2000-02-29
EE9800269A (et) 1999-02-15
IL125979A0 (en) 1999-04-11
AU720582B2 (en) 2000-06-08
NZ331705A (en) 1999-11-29
PL328917A1 (en) 1999-03-01
AU2290497A (en) 1997-11-12
WO1997039744A1 (en) 1997-10-30
KR970069038A (ko) 1997-11-07
ID16666A (id) 1997-10-30
SK144698A3 (en) 1999-05-07
EA000804B1 (ru) 2000-04-24

Similar Documents

Publication Publication Date Title
EA199800861A1 (ru) Твердая лекарственная форма, содержащая производные цизаприда, способ ее получения, продукт, содержащий твердую лекарственную форму, фармацевтическая упаковка
US6589555B2 (en) Effervescent vitaceutical compositions and related methods
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
GB2139892B (en) Solid pharmaceutical preparation containing nifedipine
HU908404D0 (en) Process for the production of preparations with 1-carnitine content
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
BR9811086A (pt) Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica
BR0115985A (pt) Preparação farmacêutica em forma de uma pasta compreendendo um ingrediente ativo ácido-lábil
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
WO2009096505A1 (ja) 注意集中力向上剤
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
FI945313A (fi) Parannetun biokäytettävyyden omaavat tabletit, jotka sisältävät dikloorimetyleenifosfonihappoa vaikuttavana aineena
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
FR2633619B1 (fr) Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
DE50011533D1 (de) Zubereitung für oral zu verabreichende Nahrungsergänzungs- und/oder Arznelmittel in Form von Tabletten
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
EA199800179A1 (ru) Способ изготовления твердых лекарственных форм, содежащих лекарства в очень малых дозах
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
HU901875D0 (en) Process for production of galenical preparations providing optimal biological accessibility of 2-hydroxi-5-methyl-laurophenon-oxim as active substance
JPH03246221A (ja) 発育促進剤
IT1212908B (it) Composti fisiologicamente attivi,loro derivati, procedimenti per la loro preparazione e prodotti farmaceutici che li contengono come principi attivi
KR920700041A (ko) 치료화합물과 그의 조성 및 용도

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU